BioCryst Pharmaceuticals Inc

1. 01

   Ahead of SPY, behind its sector fund XLV over 1 year

   1 month: +3.6% (SPY −1.6%, XLV +13.5%). 3 months: −9.2% (SPY −0.4%, XLV +15.5%). 1 year: +21.9% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.

   Daily closes, split-adjusted: BCRX, SPY and XLV · as of 4 Nov 2026

2. 02

   Below its 50- and 200-day averages

   The 4 Nov 2026 close of $8.24 was 3.6% below its 50-day average ($8.55) and 6.0% below its 200-day average ($8.77). It has closed below the 200-day for 31 sessions, since 23 Sep 2026. The 50-day average crossed below the 200-day on 27 Oct 2026, 6 sessions ago.

   Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

3. 03

   5.8 days to cover short interest

   26.6M shares were sold short at the 15 Oct 2026 settlement, 10.4% of the 255.5M shares outstanding; covering them would take 5.8 days of average volume. Short interest is reported twice a month, on a lag.

   Exchange short-interest filing · as of 15 Oct 2026

4. 04

   40% of the way up its 52-week range

   Closed at $8.24 on 4 Nov 2026: 26.6% below the 52-week high of $11.22 (9 Jul 2026) and 32.3% above the low of $6.23 (5 Feb 2026).

   Daily price bars, split-adjusted · as of 4 Nov 2026

5. 05

   Volume 2.0× its 30-session average on 4 Nov 2026

   4 Nov 2026 volume of 10.2M shares was 2.0× the average of the 30 sessions before it (5.2M), as the price fell 3.9%. SPY traded 1.5× its own average that session.

   Daily volume against a 30-session baseline · as of 4 Nov 2026

At the 4 Nov 2026 close